aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024

aTYR PHARMA INC

Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.
Phase 3 EFZO-FIT study in pulmonary sarcoidosis enrollment expected to complete Q2 2024; DSMB allowed unmodified continuation.
Launched Individual Patient Expanded Access Program for patients completing EFZO-FIT study.
Phase 2 EFZO-CONNECT study in SSc-ILD enrolling (proof-of-concept, up to 25 patients); multiple U.S. sites open.
R&D expenses $42.3M, G&A $13.0M for year 2023; no product revenue as clinical-stage biotech.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

aTYR PHARMA INC updated its the year ended December 31, 2023 guidance (reaffirmed).

Period: the year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

aTYR PHARMA INC updated its the fourth quarter ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-24-031441

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.